Lars Fruergaard Jorgensen

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, dives into the pressing issue of obesity as a complex health crisis. He shares insights on the company's innovative GLP-1 medication, addressing the major challenges of accessibility in Europe and the U.S. Jørgensen emphasizes the significance of purpose in the pharmaceutical industry and reflects on grounded leadership principles. The discussion also touches on navigating cultural differences in global teams and the value of non-linear career paths for fostering a sustainable work-life balance.

Lars Fruergaard Jorgensen, CEO of Novo Nordisk, shares insights into the competitive landscape of the pharmaceutical industry. He discusses the company's approach to high-quality products amid changing market dynamics. The rivalry in the GLP-1 market is analyzed, focusing on differentiation strategies and the impact of new FDA approvals. Jorgensen also highlights the role of partnerships, like the one with CVS, in shaping market strategies and navigating political decisions affecting U.S. manufacturing, as well as the potential of semaglutide in Alzheimer's treatment.

Novo Nordisk CEO discusses scaling up production of weight-loss drug Wegovy with Bloomberg journalists. Topics include manufacturing capacity, unit costs, pricing strategies in drug production, long-term use of weight loss drugs, administration routes, and personalized medicine.